Processa Pharmaceuticals Inc (PCSA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Processa Pharmaceuticals Inc (PCSA) has a cash flow conversion efficiency ratio of -0.520x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.90 Million) by net assets ($5.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PCSA net asset quality index to measure how much of total assets are equity-financed.
Processa Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Processa Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check PCSA cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Processa Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Processa Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Electroarges S
RO:ELGS
|
-0.001x |
|
Pacific Assets Trust plc
LSE:PAC
|
0.000x |
|
ADCORE INC. O.N.
F:ADQ
|
0.398x |
|
Betacom S.A.
WAR:BCM
|
0.199x |
|
Bowen Coking Coal Ltd
AU:BCB
|
0.207x |
|
Lithium Universe Ltd
AU:LU7
|
1.359x |
|
tokentus investment AG
MU:14D
|
N/A |
|
Shiva Mills Limited
NSE:SHIVAMILLS
|
0.061x |
Annual Cash Flow Conversion Efficiency for Processa Pharmaceuticals Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Processa Pharmaceuticals Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Processa Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.58 Million | $-11.39 Million | -2.041x | +69.21% |
| 2024-12-31 | $1.70 Million | $-11.25 Million | -6.630x | -310.21% |
| 2023-12-31 | $4.99 Million | $-8.06 Million | -1.616x | -25.70% |
| 2022-12-31 | $7.47 Million | $-9.61 Million | -1.286x | -275.88% |
| 2021-12-31 | $25.49 Million | $-8.72 Million | -0.342x | -149.64% |
| 2020-12-31 | $22.94 Million | $-3.14 Million | -0.137x | +60.08% |
| 2019-12-31 | $8.01 Million | $-2.75 Million | -0.343x | +10.20% |
| 2018-12-31 | $9.70 Million | $-3.71 Million | -0.382x | +91.38% |
| 2017-12-31 | $373.16K | $-1.65 Million | -4.434x | -1106.31% |
| 2016-12-31 | $-1.98 Million | $-871.91K | 0.441x | 0.00% |
| 2015-12-31 | $-1.98 Million | $-871.91K | 0.441x | +119.75% |
| 2014-12-31 | $1.21 Million | $-2.70 Million | -2.231x | -46.86% |
| 2013-12-31 | $1.67 Million | $-2.54 Million | -1.519x | -106.37% |
| 2012-12-31 | $2.56 Million | $-1.89 Million | -0.736x | -187.76% |
| 2011-12-31 | $2.78 Million | $-710.00K | -0.256x | -- |
About Processa Pharmaceuticals Inc
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer ce… Read more